Preliminary phase II study results of BBR2778 in combination with cyclophosphamide, vincristine, and prednisone in patients with relapsed aggressive non-Hodgkin's lymphoma.

被引：0
|
作者：
Herbrecht, R
Borchmann, P
Wilhelm, M
Morschhauser, F
Hess, G
Kutz, K
Comis, S
Laffranchi, BL
Engert, A
机构：
[1] Hop Hautepierre, Dept Hematol & Oncol, Strasbourg, France
[2] Univ Cologne, Innere Med Klin 1, Cologne, Germany
[3] Klinikum Nurnberg N, Med Klin, Nurnberg, Germany
[4] Hop Huriez, Serv Pr Bauters, Lille, France
[5] Univ Mainz, Med Klin & Poliklin 3, D-6500 Mainz, Germany
[6] Accelpharm, Basel, Switzerland
[7] Cell Therapeut Inc, Clin Dept, Milan, Italy
来源：
BLOOD | 2004年 / 104卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2489
引用
收藏
页码：682A / 683A
页数：2
相关论文
共 50 条
  • [21] A phase II study of bortezomib added to rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in patients with previously untreated indolent non-Hodgkin's lymphoma
    Cohen, Jonathon B.
    Switchenko, Jeffrey M.
    Koff, Jean L.
    Sinha, Rajni
    Kaufman, Jonathan L.
    Khoury, H. Jean
    Bumpers, Nassoma
    Colbert, Amanda
    Hutchison-Rzepka, Amanda
    Nastoupil, Loretta J.
    Heffner, Leonard T.
    Langston, Amelia A.
    Lechowicz, Mary Jo
    Lonial, Sagar
    Flowers, Christopher R.
    BRITISH JOURNAL OF HAEMATOLOGY, 2015, 171 (04) : 539 - 546
  • [22] Phase II results of bendamustine in combination with rituximab in relapsed indolent and mantle-cell non-Hodgkin's lymphoma.
    Van der Jagt, Richard H.
    Cohen, Philip
    Cheson, Bruce D.
    Tulpule, Anil
    Herst, Jordan A.
    Lemieux, Bernard
    Schwartzberg, Lee S.
    Robinson, Katherine Sue
    Oliver, Jennifer W.
    Williams, Michael E.
    BLOOD, 2006, 108 (11) : 766A - 766A
  • [23] Preliminary results from a phase II study of lenalidomide oral monotherapy in relapsed/refractory aggressive non-Hodgkin lymphoma
    Wiernik, P. H.
    Lossos, I. S.
    Tuscano, J.
    Justice, G.
    Vose, J. M.
    Pietronigro, D.
    Takeshita, K.
    Ervin-Haynes, A.
    Zeldis, J.
    Habermann, T.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [24] Phase II study of rituximab in combination with CHOP chemotherapy and GMCSF in patients with previously untreated aggressive non-Hodgkin's lymphoma.
    Venugopal, P
    Gregory, SA
    Wooldridge, J
    Yunus, F
    Adler, S
    Shammo, J
    Enschede, S
    O'Brien, T
    Franson, P
    Porter, C
    BLOOD, 2002, 100 (11) : 314B - 314B
  • [25] Treatment of patients with relapsed or refractory aggressive non-Hodgkin's lymphoma with a combination of a taxane, cyclophosphamide and rituximab.
    Krämer, A
    Zoz, M
    Krasniqi, F
    Görner, M
    Leo, E
    Ho, AD
    BLOOD, 2001, 98 (11) : 135A - 135A
  • [26] Vincristine, doxorubicin, cyclophosphamide, prednisone and etoposide (VACPE) in high-grade non-Hodgkin's lymphoma - A multicenter phase II study
    Bergmann, L
    Karakas, T
    Lautenschlager, G
    Jager, E
    Knuth, A
    Mitrou, PS
    Hoelzer, D
    ANNALS OF ONCOLOGY, 1995, 6 (10) : 1019 - 1024
  • [27] Non-pegylated liposomal doxorubicin in combination with cyclophosphamide, vincristine, prednisone and rituximab for the treatment of non-Hodgkin's lymphoma: Study of 26 patients
    Moreno, Miriam
    Sancho, Juan-Manuel
    Gardella, Santiago
    Coll, Rosa
    Garcia, Olga
    Gallardo, David
    Ribera, Josep-Maria
    MEDICINA CLINICA, 2010, 134 (02): : 72 - 75
  • [28] COMBINATION CHEMOTHERAPY OF ADVANCED NON-HODGKIN LYMPHOMA WITH BLEOMYCIN, ADRIAMYCIN, CYCLOPHOSPHAMIDE, VINCRISTINE, AND PREDNISONE (BACOP)
    SKARIN, AT
    ROSENTHAL, DS
    MOLONEY, WC
    FREI, E
    BLOOD, 1977, 49 (05) : 759 - 770
  • [29] Results of treatment with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP) for non-Hodgkin's aggressive lymphoma analyzed according to the International Prognostic Index
    Aydin, F
    Ulusoy, S
    Ovali, E
    JOURNAL OF CHEMOTHERAPY, 1997, 9 (06) : 446 - 451
  • [30] Cyclophosphamide, doxorubicin, vincristine, and prednisone versus intensive chemotherapy in non-Hodgkin’s lymphoma
    R. I. Fisher
    Cancer Chemotherapy and Pharmacology, 1997, 40 : S42 - S46
12345